Laekna Therapeutics Shanghai Co. Ltd.
Overview
Laekna Therapeutics is a clinical-stage biopharmaceutical company headquartered
in Shanghai, China, dedicated to the discovery, development, and commercialization
of innovative therapies for cancer and liver diseases. Founded in 2016, the company
operates with a global mindset, maintaining research and development operations that
span both China and the United States. Laekna focuses on addressing significant unmet
medical needs by developing differentiated drug candidates, with a particular emphasis
on oncology and metabolic-related liver conditions.
The company went public on the Hong Kong Stock Exchange, reflecting its ambition to
build a fully integrated biopharmaceutical enterprise capable of taking novel compounds
from early discovery through late-stage clinical development and ultimately to market.
Laekna's leadership team is composed of industry veterans with extensive experience in
global drug development, having previously held senior positions at major multinational
pharmaceutical companies.
Continue…Mission and Scientific Focus
Laekna Therapeutics is driven by a mission to translate cutting-edge science into
transformative medicines that meaningfully improve patient outcomes. The company
concentrates its efforts on two primary therapeutic areas:
Oncology: Developing targeted therapies and combination regimens designed to overcome
drug resistance and improve efficacy in difficult-to-treat cancers, including prostate
cancer, breast cancer, and other solid tumors.
Liver Diseases: Advancing candidates aimed at conditions such as metabolic
dysfunction-associated steatohepatitis (MASH, formerly known as NASH) and other
chronic liver disorders that carry a substantial global disease burden.
The company's scientific approach emphasizes rational drug design, precision medicine,
and the strategic pursuit of first-in-class and best-in-class molecules. Laekna combines
its in-house research capabilities with selective in-licensing and collaboration strategies
to build a diversified and clinically meaningful pipeline.
Pipeline and Product Candidates
Laekna's development portfolio is built around several key investigational assets that
target validated and emerging biological pathways. Because the company is clinical-stage,
its offerings consist of drug candidates undergoing evaluation rather than commercially
marketed products.
Afuresertib (AKT Inhibitor)
One of Laekna's lead programs is afuresertib, an orally administered AKT kinase inhibitor.
The AKT signaling pathway plays a central role in cell survival, proliferation, and
resistance to therapy across many cancer types. Afuresertib is being developed both as a
monotherapy and in combination regimens, with clinical investigation focused on cancers
such as prostate cancer and breast cancer. By targeting the PI3K/AKT/mTOR axis, the
candidate aims to disrupt tumor growth signaling and enhance the effectiveness of
companion treatments.
LAE002 and Combination Strategies
Laekna has pursued combination approaches that pair its AKT inhibitor with androgen
receptor-targeting agents and chemotherapy, seeking to address treatment resistance in
hormone-driven cancers. These combination strategies reflect the company's belief that
overcoming resistance mechanisms is essential to achieving durable clinical benefit.
LAE001 / LAE003 and Additional Oncology Assets
The company's oncology pipeline also includes candidates targeting steroidogenesis and
other cancer-relevant pathways, expanding its footprint in prostate cancer and related
malignancies. These assets are designed to complement the core AKT inhibitor program and
broaden the range of patient populations that may benefit from Laekna's therapies.
Liver Disease Program
In the liver disease space, Laekna is developing candidates aimed at MASH and associated
metabolic conditions. This area represents a large and growing global health challenge
with limited approved treatment options, positioning the company to potentially address a
major unmet need if its candidates demonstrate clinical success.
Research and Development Capabilities
Laekna operates integrated research and development functions that support the full
spectrum of drug development activities. Its capabilities include:
- Medicinal chemistry and preclinical research for identifying and optimizing drug
candidates.
- Translational science to bridge laboratory findings with clinical application.
- Clinical development expertise spanning early-phase safety studies through later-stage
efficacy trials.
- Regulatory affairs experience in navigating approval pathways across multiple
jurisdictions, including China and the United States.
The company's dual-geography operating model allows it to leverage the scientific talent
and clinical trial infrastructure of both regions, facilitating multi-regional clinical
studies that can support global regulatory submissions.
Strategic Approach
Laekna's business strategy centers on building a sustainable pipeline through a blend of
internal innovation and external partnerships. The company selectively in-licenses
promising compounds and forms collaborations that complement its internal expertise. This
approach enables Laekna to accelerate development timelines while managing risk across its
portfolio.
The company places strong emphasis on differentiation, prioritizing candidates that offer
meaningful advantages over existing standards of care, whether through novel mechanisms of
action, improved safety profiles, or the ability to address resistance. Combination therapy
development is a recurring theme, reflecting modern oncology's reliance on multi-agent
regimens to maximize patient outcomes.
Corporate Profile
- Company Type: Clinical-stage biopharmaceutical company
- Headquarters: Shanghai, China
- Operational Presence: China and the United States
- Founded: 2016
- Therapeutic Focus: Oncology and liver diseases
- Public Listing: Hong Kong Stock Exchange
Summary
Laekna Therapeutics Shanghai Co. Ltd. is a globally oriented, clinical-stage
biopharmaceutical company committed to developing innovative treatments for cancer and
liver disease. Anchored by its AKT inhibitor program and supported by a diversified
pipeline spanning oncology and metabolic liver conditions, the company seeks to deliver
differentiated therapies that address serious unmet medical needs. Through a combination
of internal research strength, strategic in-licensing, and cross-border development
capabilities, Laekna aims to advance its candidates toward regulatory approval and
commercialization, ultimately striving to improve the lives of patients facing challenging
diseases.
